IP Library Granted Patent US 7,414,041
Granted Patent B2
US 7,414,041 · App. 10/770,883 · Granted Aug 19, 2008

Reducing tetracycline resistance in living cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,414,041
App. No.
10/770,883
Granted
Aug 19, 2008
Kind
B2
Abstract

The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis . The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.

Claims (20)

1. A 6-deoxy-13-(substituted mercapto) tetracycline compound having the formula

wherein A is hydrogen or hydroxyl,

B is hydrogen or a morpholino group, and

R is alkyl, arylalkyl, or aryl.

2. The tetracycline compound of claim 1 , wherein R is ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, cyclopentyl, hexyl, decyl, cyclohexyl, benzyl, p-Cl-benzyl, p-Me-benzyl, or dihydroxypropyl.

3. The tetracycline compound according to claim 1 having the formula:

4. The tetracycline compound according to claim 1 having the formula:

5. The tetracycline compound according to claim 1 having the formula:

6. The tetracycline compound according to claim 1 having the formula:

7. The tetracycline compound according to claim 1 having the formula:

8. The tetracycline compound according to claim 1 having the formula:

9. The tetracycline compound according to claim 1 having the formula:

10. The tetracycline compound according to claim 1 having the formula:

11. The tetracycline compound according to claim 1 having the formula:

12. The tetracycline compound according to claim 1 having the formula:

13. The tetracycline compound according to claim 1 having the formula:

14. The tetracycline compound according to claim 1 having the formula:

15. The tetracycline compound according to claim 1 having the formula:

16. The tetracycline compound according to claim 1 having the formula:

17. The tetracycline compound according to claim 1 having the formula:

Assignments (3)
TERMINATION OF LIEN ON PATENTS Recorded Dec 23, 2014
From: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034700/0377 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2014
From: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034113/0910 →
SECURITY INTEREST Recorded Mar 14, 2014
From: PARATEK PHARMACEUTICALS, INC.
To: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
Reel/Frame 032448/0001 →